scholarly journals P2.09-005 The C-reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma

2017 ◽  
Vol 12 (11) ◽  
pp. S2158
Author(s):  
S. Takamori ◽  
G. Toyokawa ◽  
T. Tagawa ◽  
F. Kinoshita ◽  
Y. Kozuma ◽  
...  
2022 ◽  
Author(s):  
Masahiro Kataoka ◽  
Kuniyuki Gomi ◽  
Ken Ichioka ◽  
Takuya Iguchi ◽  
Tomoki Shirota ◽  
...  

Abstract Background/Aim: C-reactive protein to albumin ratio (CAR) has been utilized as a prognostic factor in various carcinomas. We investigated the relationship between preoperative, first postoperative day (POD1), and seventh postoperative day (POD7) CARs and the prognosis of patients with colorectal cancer (CRC). Patients and Methods: 320 patients with CRC who underwent laparoscopic radical resection between May 2011 and December 2016 were enrolled. Patients were selected into two groups, high CAR and low CAR, based on preoperative, POD1, and POD7 CARs. The relapse-free survival (RFS) and overall survival (OS) were compared between groups using propensity score matching. Results The high CAR group had a significantly worse RFS and OS (n=72/group, RFS: p<0.001; OS: p=0.002) at POD7 than those in the low CAR group. However, in preoperative and POD1 analysis, no differences were observed. Conclusion In patients with colorectal cancer, CAR of POD7 was a significant prognostic factor.


2019 ◽  
Vol 37 (11) ◽  
pp. 812.e1-812.e8 ◽  
Author(s):  
Takuya Tsujino ◽  
Kazumasa Komura ◽  
Takeshi Hashimoto ◽  
Ryu Muraoka ◽  
Naoya Satake ◽  
...  

2020 ◽  
Vol 12 ◽  
pp. 175883592096236
Author(s):  
Liu Jin ◽  
Weiling Gu ◽  
Xueqin Li ◽  
Liang Xie ◽  
Linhong Wang ◽  
...  

Background: The prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with malignant pleural mesothelioma (MPM) has been controversial according to previous investigations. Therefore, we conducted a meta-analysis to assess the potential prognostic significance of PD-L1 expression in MPM. Methods: PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were thoroughly searched for relevant original articles published before 9 April 2020. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS) and progression-free survival (PFS) were calculated. The results of the meta-analysis were verified using The Cancer Genome Atlas (TCGA) dataset. Results: In total 16 studies were included in our meta-analysis. A high PD-L1 expression was associated with a poor OS (HR = 1.53, 95% CI = 1.28–1.83, p < 0.001), but not a grave PFS (HR = 1.07, 95% CI = 0.82–1.39, p = 0.643) in MPM. Furthermore, the PD-L1 expression correlated with the sarcomatoid + biphasic type of MPM (odds ratio = 4.32, 95% CI = 2.16–8.64, p < 0.001). TCGA data indicated that PD-L1 was a significant prognostic factor for OS (HR = 2.069, 95% CI = 1.136–3.769, p = 0.0175), but not for PFS (HR = 1.205, 95% CI = 0.572–2.539, p = 0.624), which was in accordance with the results of the meta-analysis. Conclusion: A high PD-L1 expression is a significant prognostic factor for poor OS of patients with MPM. We therefore suggest that PD-L1 expression levels can be used to predict the clinical outcomes of patients with MPM in the future.


Sign in / Sign up

Export Citation Format

Share Document